@cardio_dk@Rigshospitalet Bare en kommentar: nitrater virker stort set ikke distalt for den epikardielle arterie og derfor ikke hvis sygdommen kun er lokaliseret mikrovaskullært
🫀👩🏻⚕️Dr. @JasmineMMadsen this morning presenting the PULSE-MI trial that will be starting November 14th, 2022📣📣
The trial will investigate whether pulse-dose glucocorticoid in the pre-hospital setting reduces final infarct size in #STEMI patients treated with primary PCI! 🚑 🚨
❌📣 Lars Søndergaard will talk about where we stand on interventions for aortic valve disease in 2022 tomorrow at #EuroPCR at 18.10 (CET)! 📣 Join online from home or watch on-site! 👏🏼 See you there! 🔥 #RigsHeart@Rigshospitalet@HeartCopenhagen@PCRonline
There is a paucity of standardization and comparability across studies involving coronary bifurcation lesions. The BIF-ARC document (first joint publication of @EuroInterventio and @JACCJournals) provides definitions and criteria for use in such studies.
https://t.co/HyCHitD2CI
EROSION III: OCT led to less infarct lsn stenting. No MI/ST in 1y FU, but article doesn’t stress that TLR was 0/116 (0%) in stented pts vs 9/110 (8.2%) with Med Rx for recurrent symptoms. IMO this supports routine stenting in these non-obstr lsns absent an adequately powered RCT.
In this study published in @JAMA_current, addition of PCSK9i to high-intensity statin therapy following AMI, led to greater coronary plaque regression. Congrats to @engstr_thomas and the team behind the PACMAN-AMI trial 👏🫀🚨 #JAMAJournals#RigsHeart https://t.co/yGVQ9imE5H
Up to 70% of patients with angina undergoing CAG do not have obstructive coronary artery disease (INOCA). In this review by @JasmineMMadsen, the authors dig deep into why a complete invasive diagnosis of patients with INOCA matters 🫀🚨 #RigsHeart https://t.co/Z5K570dAeE